CASE Op-Ed – RealClear Markets: Nancy Pelosi’s Price Fixing Scheme Threatens Drug Innovation
Gerard Scimeca – Chairman, CASE January 7, 2020 Addressing sky-high healthcare costs is a pressing need in our country,...
Gerard Scimeca – Chairman, CASE January 7, 2020 Addressing sky-high healthcare costs is a pressing need in our country,...
August 16, 2019 Last month, The Centers for Medicare and Medicaid Services released a new proposal which will increase price...
Yesterday, the U.S. Department of Health and Human Services released a proposal, outlining two pathways to allow for the importation...
Matthew Kandrach – President, CASE June 26, 2019 As the United States enters a long era of reducing carbon emissions,...
Matthew Kandrach – President, CASE June 3, 2019 – https://bit.ly/2KoGoEr A recent study published in Health Affairs reached a controversial conclusion, that...
Matthew Kandrach – President CASE March 4, 2019 – https://bit.ly/2EAZi6S The Senate Commerce Committee in February took up how multiple...
We’ve been vocal about how the Trump Administration has championed patients in their efforts to lower the cost of...
Matthew Kandrach – President, CASE December 21, 2018 – https://bit.ly/2CtZdlp Is it possible to have cleaner waterways across the country and,...
This week, we submitted comments to Health and Human Services (HHS) Secretary Alex Azar, urging him to reevaluate and abandon...
Almost everyone agrees patients should know what their medicines cost them, and that drug pricing should be made more clear...
🚨@USCBO just published an official score for @virginiafoxx's bill, the College Cost Reduction Act (CCRA), finding that it will save taxpayers over $185 billion over the next decade.
https://edworkforce.house.gov/news/documentsingle.aspx?DocumentID=410557
Read CBO's score: https://www.cbo.gov/publication/60285
CASE Read of the Day
Another unrealistic regulatory overreach by Biden’s EPA.